Aquatic Capital Management LLC Invests $1.02 Million in Cellebrite DI Ltd. (NASDAQ:CLBT)

Aquatic Capital Management LLC purchased a new position in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 46,068 shares of the company's stock, valued at approximately $1,015,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Nebula Research & Development LLC bought a new position in Cellebrite DI during the 4th quarter worth approximately $697,000. Lord Abbett & CO. LLC raised its holdings in Cellebrite DI by 6.7% during the 4th quarter. Lord Abbett & CO. LLC now owns 730,339 shares of the company's stock valued at $16,089,000 after buying an additional 46,119 shares during the last quarter. Oberweis Asset Management Inc. grew its holdings in Cellebrite DI by 1.2% in the 4th quarter. Oberweis Asset Management Inc. now owns 692,910 shares of the company's stock worth $15,265,000 after acquiring an additional 8,100 shares during the last quarter. Axon Enterprise Inc. purchased a new stake in shares of Cellebrite DI during the fourth quarter worth about $198,270,000. Finally, OneDigital Investment Advisors LLC bought a new position in Cellebrite DI during the 4th quarter valued at approximately $615,000. 45.88% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Needham & Company LLC restated a "buy" rating and set a $28.00 target price on shares of Cellebrite DI in a report on Wednesday, April 2nd. Lake Street Capital raised their target price on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, February 14th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI presently has an average rating of "Buy" and a consensus target price of $23.43.

Cellebrite DI Stock Down 0.6 %

Cellebrite DI stock traded down $0.11 during trading hours on Tuesday, hitting $19.60. The stock had a trading volume of 296,327 shares, compared to its average volume of 1,414,977. The stock's 50-day moving average price is $18.84 and its 200-day moving average price is $20.22. Cellebrite DI Ltd. has a 12-month low of $10.25 and a 12-month high of $26.30. The stock has a market capitalization of $4.69 billion, a P/E ratio of -14.12, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, research analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.